Methylation of rat and mouse DNA by the mushroom poison gyromitrin (cas 16568-02-8) and its metabolite monomethylhydrazine
-
Add time:08/12/2019 Source:sciencedirect.com
Consumption of false morel (Gyromitra esculenta Fr.) has been associated not only with acute poisoning, but also with a carcinogenic risk. The hydrolysis of acetaldehyde-N-methyl-N-formylhydrazone (gyromitrin (cas 16568-02-8), the main toxic component of false morel) results in the formation of the methylating agents N-methyl-N-formylhydrazine (MFH) and N-methylhydrazine (MMH) (by further hydrolysis of MFH). This study reports traces of N-7-methylguanine (N7MeGu) in liver DNA from mice and a rat treated with gyromitrin. After repeated administration of MMH, N7MeGu was identified in rat liver DNA. In mice exposed to MMH according to a dosing scheme identical to that reported to induce tumours in this species, O6-methylguanine was present in liver and kidney DNA. The results indicate that a relatively low carcinogenic risk is associated with false morel consumption. The risk may be greater in individuals with a decreased detoxification rate (acetylation) of MFH, in whom larger amounts of MMH are formed from gyromitrin.
We also recommend Trading Suppliers and Manufacturers of gyromitrin (cas 16568-02-8). Pls Click Website Link as below: cas 16568-02-8 suppliers
Prev:Gas chromatography–mass spectrometry determination of the pentafluorobenzoyl derivative of methylhydrazine in false morel (Gyromitra esculenta) as a monitor for the content of the toxin gyromitrin (cas 16568-02-8)
Next:Liver injury by the morel poison gyromitrin (cas 16568-02-8)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Renal functional response to the mushroom poison gyromitrin (cas 16568-02-8)08/14/2019
- Liver injury by the morel poison gyromitrin (cas 16568-02-8)08/13/2019
- Gas chromatography–mass spectrometry determination of the pentafluorobenzoyl derivative of methylhydrazine in false morel (Gyromitra esculenta) as a monitor for the content of the toxin gyromitrin (cas 16568-02-8)08/11/2019